EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Abstract
Authors
C.E. Rodriguez-Martinez J. Ordonez X. Carbonell-Estrany J. Fullarton I. Keary B. Rodgers-Gray I. D'Apremont S.M. Espinosa P.A. Ribeiro R. Stein N. Vain J.E. Tarride B. Paes